Loading...
Loading...
Applications for licenses pertaining to recombinant DNA (r-DNA) medications must now only be submitted with the help of the Online National Medications Licensing System (ONDLS) portal, according to a recent regulation change from the Central Drugs Standard Control Organization (CDSCO).
About the Author
Experienced Digital Marketer with a demonstrated history of working in the Internet industry. He likes to write about the latest technology trends, Skilled in Digital Marketing likes. Search Engine Optimization, SMO, SEM, PPC, Content Writing, and, Designing, etc.
Related articles
New Drug Manufacturing and Clinical Trial Rules Updated in 2026: What You Should Know?
2026-03-13
CDSCO Releases New Guidelines for Compounding of Offences Under the Drugs and Cosmetics Act
2026-02-26
Regulation of Medical Device Pricing and Quality in India: Key Government Measures
2026-02-20
CDSCO Releases Risk Classification List for Oncology Medical Devices
2026-02-12
Government Notifies CGHS Drug Procurement Policy 2026
2026-01-24
Draft Medical Devices Rules Amendment 2025: Regulatory Changes in Registration, Labelling, and Compliance
2025-12-15